Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;10(1):34-39.
doi: 10.1097/UPJ.0000000000000350. Epub 2022 Dec 12.

Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a Multi-disciplinary Uro-oncology Practice

Siddharth Ramanathan  1   2 , Andrew Korman  2 , Sadhna Ramanathan  2 , Howard Korman  2 , Michael I Ghilezan  3 , Michael Levin  2 , Kirk Wojno  2 , Alvaro Martinez  3 , Savitha Balaraman  4
Affiliations

Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a Multi-disciplinary Uro-oncology Practice

Siddharth Ramanathan et al. Urol Pract. 2023 Jan.

Abstract

Introduction: Prior to the 2017 Philadelphia Consensus Conference guidelines, genetic testing for prostate cancer was conducted based on personal and family history of malignancy pursuant to National Comprehensive Cancer Network recommendations. The updated 2019 guidelines addressed the subject of genetic testing by endorsing point-of-care genetic testing and referral to genetic counseling. However, limited literature is available regarding successful implementation of a streamlined method for genetic testing. This paper explores the benefits of implementing an on-site guideline-based genetic testing process for prostate cancer patients.

Methods: Data were retrospectively reviewed for 552 prostate cancer patients seen in a uro-oncology clinic since January 2017. Prior to September 2018 genetic testing was recommended based on National Comprehensive Cancer Network guidelines, and swabs for testing were procured off-site 1 mile from the clinic (n = 78). After September 2018 genetic testing was recommended based on the Philadelphia Consensus Conference guidelines, and swabs for testing were procured at the clinic itself (n = 474).

Results: A statistically significant increase in testing compliance was observed after the implementation of on-site, guideline-based testing. Genetic testing compliance increased from 33.3% to 98.7%. The time to receive the genetic test results was also reduced from 38 days to 21 days.

Conclusions: The implementation of an on-site, guideline-based genetic testing model for prostate cancer patients significantly improved compliance with genetic testing to 98.7% and decreased the time to receive genetic test results by 17 days. Adopting a guideline-based model with on-site genetic testing can significantly improve the detection rate for pathogenic and actionable mutations and increase the utilization of targeted therapies.

Keywords: compliance; genetic testing; prostatic neoplasms; workflow.

PubMed Disclaimer

Comment in

  • Editorial Commentary.
    de la Calle CM, Singla N. de la Calle CM, et al. Urol Pract. 2023 Jan;10(1):39. doi: 10.1097/UPJ.0000000000000350.01. Epub 2023 Jan 1. Urol Pract. 2023. PMID: 36643963 Free PMC article. No abstract available.